Hohimer Wealth Management LLC Acquires 171 Shares of Edwards Lifesciences Co. (NYSE:EW)

Hohimer Wealth Management LLC grew its holdings in Edwards Lifesciences Co. (NYSE:EW) by 2.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,246 shares of the medical research company’s stock after purchasing an additional 171 shares during the quarter. Hohimer Wealth Management LLC’s holdings in Edwards Lifesciences were worth $692,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. Martin Capital Advisors LLP raised its position in shares of Edwards Lifesciences by 0.5% in the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after acquiring an additional 128 shares during the period. Legacy Wealth Asset Management LLC raised its position in shares of Edwards Lifesciences by 0.8% in the 4th quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after acquiring an additional 134 shares during the period. Chapin Davis Inc. raised its position in shares of Edwards Lifesciences by 1.7% in the 1st quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock valued at $817,000 after acquiring an additional 140 shares during the period. Johnson Financial Group Inc. raised its position in shares of Edwards Lifesciences by 23.0% in the 4th quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock valued at $59,000 after acquiring an additional 144 shares during the period. Finally, Valley National Advisers Inc. raised its position in shares of Edwards Lifesciences by 6.0% in the 1st quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 152 shares during the period. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the topic of several research analyst reports. The Goldman Sachs Group initiated coverage on shares of Edwards Lifesciences in a report on Thursday, May 30th. They set a “buy” rating and a $107.00 target price on the stock. Citigroup raised their target price on shares of Edwards Lifesciences from $105.00 to $106.00 and gave the stock a “buy” rating in a report on Wednesday, July 10th. Mizuho raised their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. Stifel Nicolaus raised their target price on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a report on Friday, April 26th. Finally, Wells Fargo & Company raised their target price on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a report on Friday, April 26th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $96.76.

Edwards Lifesciences Stock Down 2.0 %

Shares of NYSE:EW traded down $1.77 during midday trading on Tuesday, hitting $87.73. The stock had a trading volume of 4,418,165 shares, compared to its average volume of 3,404,045. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. The business’s 50-day simple moving average is $89.06 and its 200-day simple moving average is $86.60. The company has a market cap of $52.87 billion, a P/E ratio of 38.39, a PEG ratio of 3.33 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. On average, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the completion of the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at $14,639,824.29. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total value of $1,212,624.00. Following the completion of the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at $14,639,824.29. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $4,378,659.44. The disclosure for this sale can be found here. Insiders sold a total of 81,099 shares of company stock valued at $7,003,553 over the last ninety days. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.